Skip to main content
SGMT
NASDAQ Life Sciences

Sagimet Q3 Loss Widens to $19.1M as AURORA Phase 3 Ramps; $275.8M Cash Plus $107.5M October Net

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$11.4
Mkt Cap
$802.593M
52W Low
$4.5
52W High
$11.449
52W Position info
153% above low
Off High info
at 52W high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

SGMT has more than doubled off its 52-week low of $4.5.

Summary

Sagimet's Q3 2026 net loss widened to $19.1M on a 68% jump in R&D for the AURORA Phase 3 acne trial, leaving $275.8M in cash and securities before the October offering added about $107.5M net. The ATM was terminated with no shares sold.


Key Events · Earnings and Guidance · SGMT

  • Q3 Loss Widens on Phase 3 Spend

    Net loss was $19.1M for Q3 2026 versus $12.9M a year earlier; R&D rose 68% to $16.3M, driven by the AURORA Phase 3 trial and TVB-3567 Phase 1.

  • Liquidity Covers At Least 12 Months

    Cash, cash equivalents and marketable securities totaled $275.8M at September 30, 2026, including $27.5M of investor funds received before the October offering closed; management says this plus the October net proceeds funds at least 12 months.

  • October Offering Adds ~$107.5M Net

    The October 1, 2026 offering sold 8,750,010 shares at $10.00 and 2,750,010 pre-funded warrants at $9.9999 for about $115.0M gross and an estimated $107.5M net.

  • ATM Terminated With No Sales

    The August 2025 at-the-market program, sized at up to $75.0M, was suspended and its prospectus supplement terminated effective September 30, 2026; no shares were sold under it.


Analysis · SGMT · Life Sciences

The wider loss reflects the cost of running a pivotal US Phase 3 acne trial: R&D rose 68% to $16.3M in the quarter. That spending is funded — $275.8M of cash and securities at September 30 plus roughly $107.5M net from the October offering covers at least the next 12 months, so there is no near-term financing need. The trade-off is dilution already taken: the October deal added 8.75M shares at $10.00 plus 2.75M pre-funded warrants, and the ATM was terminated with zero sales. MASH work is parked until non-dilutive money appears, which concentrates the story on AURORA enrollment and the TVB-3567 Phase 2 start before year-end.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SGMT was trading at $11.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $802.6M. The 52-week trading range was $4.50 to $11.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SGMT - Latest Insights

SGMT
Nov 12, 2026, 7:32 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $11.40
Real-time Price: $11.41 info
Change: +$0.0132 (+0.12%) info
Market Cap: $802.593M info
SGMT
Oct 01, 2026, 5:41 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $9.24
Real-time Price: $11.41 info
Change: +$2.17 (+24%) info
Market Cap: $802.593M info
SGMT
Sep 30, 2026, 6:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.03
Real-time Price: $11.41 info
Change: +$1.38 (+14%) info
Market Cap: $802.593M info
SGMT
Sep 30, 2026, 5:53 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $10.03
Real-time Price: $11.41 info
Change: +$1.38 (+14%) info
Market Cap: $802.593M info
SGMT
Sep 30, 2026, 6:19 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $9.99
Real-time Price: $11.41 info
Change: +$1.42 (+14%) info
Market Cap: $802.593M info